Enfortumab vedotin
- Generic Name
- Enfortumab vedotin
- Brand Names
- Padcev
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1346452-25-2
- Unique Ingredient Identifier
- DLE8519RWM
- Background
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to bren...
- Indication
Enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting. Enfortumab vedoti...
- Associated Conditions
- Locally Advanced Urothelial Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Urothelial Cancer
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.